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Interleukin-1 (IL-1) induces degradation via hyper-
expression of an array of genes, including metallopro-
teinases (MMP), in cartilage cells during articular de-
generative diseases. In contrast, natural ligands for
peroxisome proliferator-activated receptors (PPARs)
display protective anti-cytokine effects in these cells.
We used the PPAR agonist rosiglitazone (Rtz) to inves-
tigate PPAR- isotype on IL-1-target genes. Immunocy-
tochemistry, electrophoretic mobility shift, and tran-
sient transfection assays revealed a functional PPAR-
in chondrocytes in vitro. Rtz displayed significant inhi-
bition of IL-1 effects in chondrocytes. Low Rtz concen-
trations (close to Kd values for PPAR-, 0.1 to 1 M)
inhibited the effects of IL-1 on 35S-sulfated proteogly-
can production and gelatinolytic activities and down-
regulated MMP1 expression at mRNA and protein levels.
We have investigated the mechanism of action of Rtz
against IL-1-mediated MMP1 gene hyperexpression.
Rtz effect occurs at the transcriptional level of the
MMP1 promoter, as observed in transiently transfected
cells with pMMP1-luciferase vector. Transient expres-
sion of wild type PPAR- enhanced Rtz inhibitory effect
in chondrocytes, whereas a mutated dominant negative
PPAR- abolished it, supporting the role of PPAR- in
this effect. MMP1 gene promoter analysis revealed the
involvement of a cis-acting element located at 83 to
77, shown to be a composite PPRE/AP1 site. Gel mobil-
ity and supershift assays demonstrated that PPAR- and
c-Fos/c-Jun proteins bind this cis-acting element in a
mutuallyexclusiveway.OurdatahighlightanewPPAR--
dependent inhibitory mechanism on IL-1-mediated
cartilage degradation occurring through DNA binding
competition on the composite PPRE/AP1 site in the
MMP1 promoter.
Peroxisome proliferator-activated receptor  (PPAR-)1 natu-
ral ligands, such as 15-deoxy-12,14-prostaglandin J2 (15d-
PGJ2), exert anti-IL-1 effects in cartilage cells in vivo and in
vitro. Intra-articular injection of 15d-PGJ2 inhibits adjuvant-
induced arthritis in rats (1) and addition of 15d-PGJ2 to IL-1-
treated human or rat chondrocytes in culture counteracts IL-1-
induced effects (2–4). As IL-1 plays a central role in the
degradation of cartilage in rheumatoid arthritis and osteoarthri-
tis (5, 6), the above data suggest a role for PPAR- in cartilage
homeostasis leading to new directions in therapeutic research.
PPAR- is a member of the nuclear receptor superfamily of
ligand-dependent transcription factors. PPAR- forms a het-
erodimeric complex with the retinoid X receptor (7) and binds
to specific nucleotide motifs (direct repeats with single spacing,
DR1) located in the promoter of target genes. Natural ligands
such as 15d-PGJ2 have been shown to activate PPAR-, yet the
true physiological ligands of this receptor remain elusive. Nu-
merous synthetic PPAR- activators have been identified, in-
cluding thiazolidinediones (such as rosiglitazone (Rtz)) used in
the treatment of type II diabetes (8). PPAR- was first demon-
strated to regulate adipocyte differentiation, and it has been
recognized recently (9) to be implicated in the modulation of
cancer cells growth and inhibition of the inflammatory process
in immunocompetent cells (10–13) and other cell types (14),
including cartilage cells (2–4). Most anti-inflammatory effects
have been observed with 15d-PGJ2, a poor agonist of PPAR-,
whereas synthetic PPAR- ligands such as Rtz were less effec-
tive or not active, despite their higher affinity for the receptor
(Rtz Kd  100 nM). Thus, the question regarding the exact role
and the implication of PPAR- in these effects has been largely
discussed and documented in cells from the immune system.
Overexpression of PPAR- in macrophages maximized the abil-
ity of diverse PPAR- agonists to inhibit the expression of
inflammatory response genes consistent with a PPAR--medi-
ating anti-inflammatory mechanism (15, 16). Other data indi-
cated PPAR--independent anti-inflammatory effects. Treat-
ment of macrophages derived from PPAR--null embryonic
stem cells with high concentrations of synthetic PPAR- li-
gands was reported recently (17) to inhibit the induction of the
inducible nitric-oxide synthase and COX2. Similar data were
observed in the RAW 264.7 macrophages (18–20).
In sharp contrast, the role of Rtz-activated PPAR- as an
antagonist of IL-1-induced cartilage degradation is largely
unknown. The aim of this work was to analyze this role
through the effects of the hypolipidemic drug rosiglitazone on
IL-1-induced target genes active in the degradative process of
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matrix proteins synthesized by culture chondrocytes. We report
a PPAR--dependent inhibitory mechanism on IL-1-induced
MMP1 expression acting through a new composite PPRE/AP-1
site at positions 83 to 71 upstream from the MMP1 rabbit
gene transcription start site.
EXPERIMENTAL PROCEDURES
Isolation and Culture of Chondrocytes from Rabbit Articular Carti-
lage—Articular chondrocytes were cultured as described previously
(21). Briefly, 5-week-old Fauve de Bourgogne rabbits (CPA, Orleans,
France) were killed, and the femoral, humeral, and tibial articular
cartilages were removed under sterile conditions. Thin slices of carti-
lage were sequentially digested with 0.2% hyaluronidase and 0.2%
collagenase in Geys’ balanced salt solution (Eurobio, Les Ulis France).
The resulting cell suspension was plated at 105 cells per cm2 (high
density) into 75-cm2 flasks or 6-well plates and incubated in Ham’s F-12
medium (Invitrogen) containing 10% fetal calf serum (FCS), 100 IU/ml
penicillin, and 100 g/ml streptomycin. Cells were then cultured at
37 °C in an atmosphere of 8% CO2 in air, and the medium was changed
once until the cells were confluent (day 6 of the primary culture). The
medium was replaced with 2% FCS/Dulbecco’s modified Eagle’s me-
dium (DMEM) (Invitrogen) to which was added either IL-1 alone
(Immugenex Corp., Los Angeles) or combined with Rtz at concentra-
tions ranging between 0.1 and 10 M. Cells were incubated for 18 h and
analyzed as below.
Immunological Studies—Chondrocytes were cultured in 4-chamber
labtek slides (Merck) and incubated for 18 h in 2% FCS/DMEM with or
without 1 M Rtz. After being washed in PBS, cells were fixed with 4%
paraformaldehyde in 0.1 M sodium phosphate and washed in blocking
buffer (PBS with 5% bovine serum albumin and 0.2% Tween 20). Fixed
cells were then exposed to polyclonal PPAR- antibody (Santa Cruz Bio-
technology) diluted at 1:100 in blocking buffer for 2 h at room temperature
(20 °C) in a humid chamber. After a quick rinse in 0.1% PBS/Tween, cells
were exposed to the rabbit anti-goat Alexa 546-coupled secondary anti-
body (Molecular Probes and Invitrogen) diluted at 1:800 for 2 h. Cells were
rinsed in PBS/Tween and mounted with Vectashield. The slides were
observed with a Nikon Labophot 2 and photographed with a Spot camera
driven by the Spot Jr software (Diagnostic Instrument). Controls were
made by omission of primary antibody.
Nuclear Extract and Electrophoretic Gel Mobility Shift Assay
(EMSA)—Nuclear proteins were extracted as described by Riquet et al.
(22). Briefly, cells were treated with various effectors for 60 min and then
scraped on ice and washed twice in a PBS solution. After a centrifugation
at 800 g for 5 min at 4 °C, the pellet was dissolved in an RSB 1 buffer
(10 mM Tris, 10 mM NaCl, 3 mM MgCl2, 0.002% NaN3) plus 0.5% Nonidet
P-40 with a protease mixture inhibitor (Roche Applied Science). This step
was repeated once. Cell lysate was centrifuged at 5100  g for 5 min at
4 °C. The pellet was dissolved in buffer C (20 mM Hepes, pH 7.4, 420 mM
NaCl, 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.01% NaN3). After a
30-min incubation, nuclear proteins were centrifuged at 105,000  g for
15 min at 4 °C. The supernatant was mixed with an equal volume of
buffer D (20 mM Hepes, 50 mM KCl, 0.2 mM EDTA, 0.01% NaN3), collected,
and stored in liquid nitrogen. Double-stranded oligonucleotide was la-
beled by the Klenow fragment of DNA polymerase in the presence of
[-32P]dCTP. Samples of 6 g of each nuclear extract were incubated with
50 fmol of double-stranded radiolabeled oligonucleotides in 6 l of EMSA
mix (50 mM Hepes, pH 7.9, 50% glycerol, 5 mM EDTA, and 300 mM KCl)
plus 1 g of poly[d(I-C)], 600 ng of bovine serum albumin, 10 mM dithio-
threitol, 1.5 ng of salmon sperm DNA in a final volume of 15 l. Incuba-
tion was performed for 20 min at room temperature. The samples were
analyzed by electrophoresis in 6 or 8% denaturing polyacrylamide gels
containing, respectively, 1 or 0.25 TBE for 180 min at 130 V, transferred
to 3MM paper (Whatman), dried under vacuum at 80 °C, and exposed to
biotech x-ray film (Amersham Biosciences). To determine the specificity of
the DNA protein complex, competition assay was performed using a 50- or
100-fold molar excess of the corresponding unlabeled, double-stranded
oligonucleotide. PPAR- (sc-1984X), PPAR- (sc-1983X), and PPAR- (sc-
1985X) goat polyclonal antibodies, p50 goat polyclonal antibody (sc-
1190X), p65 mouse monoclonal antibody (sc-8008X), Fos (253X), Fra-1
(sc-183X), Fra-2 (sc-171X), c-Fos (sc-52X), and c-Jun (sc-45X) rabbit poly-
clonal antibodies were purchased from Santa Cruz Biotechnology (Tebu,
France). For supershift analysis, antibodies were added (2 g) to the
incubation for 15 min at 4 °C before the binding reaction. Three double-
stranded oligonucleotides were constructed, containing either the canon-
ical PPRE site from the acyl-CoA oxidase gene, 5-AGCTGGACCAGGA-
CAAAGGTCACGTT-3, the composite PPRE/AP-1 element 5-
GGATCCTATAAAGCATGAGTCACACAGCCCTCAGCT-3 at 83 to
71 in the rabbit MMP1 gene, or the NF-B site at 3029 to 2994 5-
GGGAATTGAATATGGAAAAACACCAACATAGTTGAG-3 (23).
Transient Transfection and Luciferase Assay—Rabbit chondrocytes
were cultured in Ham’s F-12 containing 10% FCS as described above,
trypsinized, and plated in 6-well plates. Cells were then transfected at
70% confluence via a calcium phosphate precipitation method. Briefly,
cells were incubated for 4 h with the precipitate obtained with 0.02 M
CaCl2 in a Hepes buffer, pH 7.0, and 1.5 g of DNA/well, i.e. either by
adding 1 g of the 3xPPRE-TK-Luc construct (a gift from Dr. P.
Grimaldi, Nice, France) or the chimeric MMP1 promoter-luciferase
construct with 500 ng of -galactosidase expression vector. Each point
was made in triplicate. Cells were then lysed in 400 l of lysis buffer
(Promega, France). Luciferase assay was performed using 20 l of cell
lysis on a Lumat LB 9507 luminometer (Berthold, France). Efficiency of
the transfection was shown to be 50–70% of total cells, as determined
by -galactosidase assay (Promega, France).
Measurement of [35S]Sulfate Incorporation into Proteoglycans (PG)—
The incorporation of [35S]sulfate into PG by articular chondrocytes was
assessed as described previously (24). At confluency, chondrocytes were
incubated in 2% FCS/sulfate-free DMEM plus 1.5 Ci/ml Na2[
35SO4]
(75 MBq/ml, Amersham Biosciences) for 18 h in the presence or absence
of effectors. Controls were prepared without any additive compound.
Each point was prepared in triplicate. Proteoglycans were extracted
from culture media and cell layer at 4 °C by incubation with 3 M
guanidinium chloride in 0.05 M Tris-HCl (Merck), pH 7.4, in the pres-
ence of protease inhibitors (10 mM Na2EDTA (Sigma), 5 mM benzami-
dine (Merck), and 0.1 mM 6-aminohexanoic acid (Prolabo, Fontenay,
Bois, France). Aliquots of the guanidinium extract were then spotted on
a set of Whatman 3MM paper and allowed to dry. The set was used to
quantify total high molecular weight/highly charged sulfated PG sub-
units, which were precipitated with 5% cetylpyridinium chloride in 0.3
M NaCl (Sigma) according to Larsson and Kuettner (25). Scintillation
liquid was added to each strip, and the strips were counted in a Packard
tricarb -spectrometer. Each measurement was made in triplicate. For
each experiment, the amount of DNA was measured in sister flasks by
the fluorometric method described by Kapuscinski and Skoczylas (26).
Results were calculated as mean  S.D. cellular or medium dpm/10 g
of DNA of four similarly treated wells. Results are presented as total
radiolabeled PG expressed in percent of controls performed with cells
from three different animals.
Zymography—Zymographic analysis of gelatinase activities was per-
formed by using cell culture supernatants (10 l). The chondrocyte-
conditioned medium, mixed with 4 sample buffer (250 mM Tris base,
2.5% SDS, 12.5% glycerol, 0.1% bromphenol blue), was subjected to
electrophoresis at 4 °C on a 0.1% SDS-polyacrylamide gel containing 1
mg/ml gelatin. After electrophoresis, the SDS was removed by washing
the gel in a 2.5% Triton X-100 for 30 min with one change of the
incubating buffer. The gel was then incubated at 37 °C for 24 h in
incubation buffer (50 mM Tris-HCl, pH 7.4, 5 mM CaCl2, 0.02% NaN3, 1
M ZnCl2, 0.0015% Brij-35, 2.5% Triton X-100). Gels were stained with
0.5% Coomassie Blue, 10% acetic acid, 30% methanol buffer and
destained with sequential discoloration solutions until the digested
bands were clearly separated. A molecular marker was electrophoresed.
The levels of the 92-, 72-, and 53/58-kDa gelatinolytic activities were
quantified by video densitometry.
Western Blotting—Proteins were extracted from culture medium by
addition of 5 volumes of cold acetone and centrifuged at 12,000  g for
5 min. The pellet was collected in 10 mM phosphate buffer containing
protease inhibitors. Proteins were size-separated by SDS-PAGE in 10%
polyacrylamide gel. A Colored Rainbow mix, code RPN 756 (Amersham
Biosciences), was used as the molecular weight marker. The gel was
electroblotted to nitrocellulose (Bio-Rad) in transfer buffer (25 mM
Tris-HCl, 192 mM glycine, pH 8.3) in a Transblot Cell (Bio-Rad). Equal
transfer of proteins was confirmed by staining the nitrocellulose with
Ponceau Red (0.2% w/v H2O diluted 99:1 in 10% trifluoroacetic acid).
The MMP1 antibody (polyclonal goat anti-human MMP1, Santa Cruz
Biotechnology (Tebu, France)) was diluted at 1:200 and used as primary
antibody overnight at 4 °C. A peroxidase-conjugated rabbit anti-goat
IgG (Dako P0160) was used as secondary antibody at 1:2000 and incu-
bated for 1 h at room temperature. Blots were revealed by enhanced
chemiluminescence as instructed by the manufacturer (ECL, Amer-
sham Biosciences). Semi-quantitative scanning densitometry was per-
formed with the NIH image software (results were standardized using
Ponceau Red staining for homogeneity).
Production of Rabbit cDNA Probes by RT-PCR—MMP probes were
generated by RT-PCR in accordance with the human sequences, se-
lected in a domain conserved across species for MMP1, MMP3, and
MMP13 (GenBankTM accession numbers M17821, M25664, and
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M002427, respectively). Total RNA was prepared from control or IL-1
(10 ng/ml)-treated rabbit chondrocytes and synthesized into cDNA us-
ing Moloney murine leukemia virus-reverse transcriptase (Promega).
Briefly 1 g of total RNA was reverse-transcribed at 42 °C for 1 h in a
25-l reaction according to the manufacturer’s instructions. The result-
ing cDNA was amplified for PCR on a DNA thermal cycler
(PerkinElmer Life Sciences) using the following program: 96 °C for 5
min, followed by 35 cycles of 96 °C for 30 s, 55–60 °C for 30 s, and 72 °C
for 1 min. A 15-min 72 °C extension step completed the reaction. PCR
products were subcloned in pGEM vector.
Rabbit MMP1 Promoter Cloning—Genomic DNA from rabbit chondro-
cytes was extracted by Trizol (Invitrogen), according to the supplier’s
instructions. MMP1 promoter primers were chosen in the GenBankTM
accession number M17820: 5-CGGGGTACCGACCAAGGACTCAAGA-3
and 5-ACTGAGAAGGAAGACACTCGAGCGG-3. A proofreading Taq
(Pfu Turbo, Stratagene, France) was used for PCR with the long range
method (hot start: 96 °C, 5 min), 10 cycles ((98 °C, 30 s; 57 °C, 1 min;
72 °C, 5 min)), 20 cycles ((98 °C, 30 s; 57 °C, 1 min; 72 °C, 5 min with an
incrementation of 20 s per cycle)), and terminal extension at 72 °C for 10
min. The 3.5-kb MMP1 promoter fragment was purified with Geneclean
Sprint kit (Bio 101) and inserted in pGL3-basic vector (Promega, France)
using KpnI and XhoI restriction sites.
Mutagenesis—All mutants were generated with the Quick Change
site-directed mutagenesis kit from Stratagene (France). The dominant
negative PPAR- was constructed following the procedure (27) de-
scribed by Gurnell et al. (28) in which Leu468 and Glu471 were mutated
to alanine in the ligand binding domain. A double point mutation
(AAAGCA to AGTAGT) was introduced into the proximal PPRE-like
site 83 to 78 to generate the pGL-MMP1-PPRE, by using the
forward sequence primer 5-TCAAGAGGATGTTATAGTAGTTGAGT-
CACACAGC-3, corresponding to region 99 to 65 of the rabbit
MMP1 promoter.
DNA Sequencing—Automated sequencing was performed by Genome
Express to confirm the identity of all DNA probes and constructs used
in the study.
RNA Isolation and Northern Blot—Total RNA was extracted from
cells by a single-step method using Trizol reagent (Invitrogen). Samples
of 10 g of total RNA were used for Northern blot analysis. The rabbit
MMP1, -3, and -13 cDNA probes were synthesized by RT-PCR. All
probes were labeled by random priming with [-32P]dCTP (Amersham
Biosciences) to a specific activity of 108 to 109 cpm/g. Results were
normalized by using a human glyceraldehyde-3-phosphate dehydrogen-
ase probe and quantified using Studio Scan II (Agfa, Paris, France) with
the NIH software.
Statistical Analysis—Values are expressed as the mean  S.D. Sta-
tistics were performed by analysis of variance. Multiple comparisons
were performed with the Tukey test. Differences between groups were
considered significant for p  0.05.
RESULTS
Presence of Functional PPAR- in Cultured Articular Chon-
drocytes—PPAR- displayed nuclear localization in our in vitro
model of cultured rabbit chondrocytes, independently of Rtz
treatment (Fig. 1A). EMSA was carried out with nuclear ex-
tracts from 1 M Rtz-treated chondrocytes and an oligonucleo-
tide containing the canonical PPRE sequence described under
“Experimental Procedures.” Fig. 1B showed the involvement of
the PPRE-containing oligonucleotide in a robust protein-DNA
complex. Binding specificity was confirmed by using an 80-fold
molar excess of the unlabeled oligonucleotide. This complex
was supershifted in the presence of anti-PPAR- antibody.
Finally, Rtz increased luciferase activity in chondrocytes tran-
siently transfected with a PPRE-luciferase gene reporter, in a
dose-dependent manner from 0.1 to 1 M. Maximum activity
(4-fold induction) was observed at 1 M and stayed in plateau
up to 10 M (Fig. 1C).
Low Concentrations of Rtz (1 M) Selectively Inhibit IL-1-
induced Proteoglycan Degradation, Gelatinolytic Activities, and
MMP1 Production—Chondrocytes were incubated for 18 h in
sulfate-free medium in the presence of 35S-radiolabeled sulfate
with or without effectors. 35S-Sulfate incorporation into
cetylpyridinium chloride-precipitable PG was measured in the
culture medium. Fig. 2A shows that in the presence of IL-1
alone total 35S-sulfated PG were decreased by 35  10%, from
6.35  0.56 104 dpm/10 g DNA in control conditions to 4.12 
0.39 104 dpm/10 g DNA (p  0.01). Addition of Rtz reproduc-
ibly induced a dose-dependent stimulation of 35S-sulfated PG
and fully restored control values at doses as low as 1 M, being
stable at 10 M. These results show that low concentrations
(1 M) of Rtz counteract the detrimental effect of IL-1 on
proteoglycans production.
We then asked whether this inhibitory effect involved the
inhibition of the documented induction of matrix metallopro-
teinases production induced by IL-1 in chondrocytes. Among
them MMP1 can be studied by gelatinolytic activity at an
apparent molecular mass of 53/58 kDa. In our control condi-
tions, chondrocytes secreted two main gelatinolytic activities at
apparent molecular masses of 92 and 72 kDa, presumably
corresponding to MMP9 and MMP2, respectively. Fig. 2B is
representative of three separate experiments. Treatment with
IL-1 alone caused an augmentation of the 92-kDa band and
induced a new gelatinolytic activity at an apparent mass of
53–58 kDa, whereas no modification of the 72-kDa band was
observed. Quantification analysis of the 92- and 53–58-kDa
bands was done as relating to the 72-kDa band. The 92-kDa
FIG. 1. Cultured rabbit articular chondrocytes express a func-
tional PPAR-. A, immunocytochemistry of PPAR-. Rabbit articular
chondrocytes were cultured at high density and incubated for 18 h in 2%
FCS/DMEM in the absence (Control) or presence of 1 M Rtz (Rtz).
Intracellular localization of PPAR- was performed using an anti-
PPAR- antibody. PPAR- localization appears predominantly nuclear
independently of Rtz treatment of the cells. DAPI, 4,6-diamidino-2-
phenylindole. B, EMSA. Nuclear extracts from chondrocytes incubated
with 1 M Rtz were incubated with a [-32P]ATP-labeled oligonucleotide
containing the canonical PPRE sequence from the acyl-CoA gene. Bind-
ing specificity was confirmed using an 80-fold molar excess of unlabeled
oligonucleotide. A specific supershifted complex was observed in the
presence of anti-PPAR- antibody (*Ss). C, transient expression. Chon-
drocytes were transiently transfected with a 3xPPRE-luciferase re-
porter plasmid and by -galactosidase vector. Cells were treated with
increasing concentrations of Rtz for 18 h (0.1–10 M). Cell extracts were
assayed for luciferase activity. The activities were corrected for trans-
fection efficiency by -galactosidase activity and expressed as fold in-
duction relative to the level in untreated cells. Each assay was per-
formed in triplicate. Data are the mean  S.D. of three separate
experiments performed with cells from different animals (**, p  0.01
versus nontreated cells).
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gelatinolytic activity was decreased by 40 3% and by 50 5%
(p  0.01) with 1 and 10 M Rtz, respectively. The IL-1-
induced 53/58-kDa gelatinolytic activity was decreased by 35
5% and by 55  7% (p  0.01) with 0.5 and 1 or 10 M Rtz,
respectively. Similar results were observed at the protein level
as shown by Western blot analysis. Fig. 2C is representative of
three separate experiments. Scanning densitometry of the
bands showed that the mean  S.D. of IL-1 overexpression of
the MMP1 signal (apparent molecular mass, 52 kDa) was sig-
nificantly decreased by Rtz in a dose-dependent manner, i.e. by
41  3.8% (p  0.01), 70  11% (p  0.001), and 81  6% (p 
0.001), with 0.1, 0.5, or 1 M Rtz, respectively. These concurring
data strongly suggest that the gelatinolytic activity observed at
53/58 kDa corresponds to the MMP1 protein.
The Inhibitory Effect of Rtz on IL-1-induced MMP1 mRNA
Expression Is a Direct Mechanism—Steady state levels of
MMP1 mRNA were analyzed by Northern blotting, as com-
pared with MMP3 and MMP13 mRNAs. As shown in Fig. 3A,
MMP1, -3, and -13 mRNA levels were close to detection limits
in control conditions, but were strongly expressed in the pres-
ence of IL-1. Co-treatment of Rtz and IL-1 decreased mRNA
levels of MMP1, -3, and -13 by 25, 10, and 15%, respectively (0.5
M Rtz), and by 70, 40, and 55% (1 M Rtz) (Fig. 3B). This effect
did not appear mediated by protein synthesis, as cycloheximide
did not modify the inhibitory effect of Rtz on MMP1, -3, or -13
mRNA levels (Fig. 3A). These data suggest that down-regula-
tion of IL-1-induced proteoglycan degradation by Rtz may be
mediated by inhibition of MMP production by chondrocytes. We
then focused on the Rtz effect on MMP1 gene transcription.
The Inhibitory Effect of Rtz on IL-1-induced MMP1 Gene Is
Transcriptional and Requires PPAR-—Chondrocytes were
transiently transfected with a pMMP1-luciferase construct
containing 3448 bp of the 5-flanking region of the rabbit
MMP1 gene linked to the luciferase gene and supplemented
with IL-1 and/or Rtz as described under “Experimental Pro-
cedures.” Each point was done in triplicate, and this experi-
ment was performed three times with different animals for the
dose-response curve and twice for the dominant negative ex-
periments. Fig. 4 showed that luciferase activity was not mod-
ified by addition of 1 M Rtz alone, whereas it was increased
4-fold by IL-1. Co-treatment of chondrocytes with IL-1 and
increasing concentrations of Rtz led to a dose-dependent reduc-
tion of MMP1 promoter activity corresponding to 23  3% and
42  3% (n-1  17, p  0.001) inhibition with 0.5 and 1 M Rtz,
respectively, as compared with IL-1-treated cells. In addition,
a more pronounced inhibitory effect of Rtz (60  1% inhibition,
n-1  11 p  0.001) was observed in cells overexpressing the
wild type PPAR-. The involvement of PPAR- in the inhibitory
effects of Rtz on MMP1 transcription was further demonstrated
by using a mutant dominant negative of PPAR- (DN-PPAR-).
Preliminary experiments showed that the DN-PPAR- mutant
abolishes the stimulatory effect of Rtz on a canonical PPRE-
luciferase construct when co-expressed in chondrocytes (data
not shown). As shown on Fig. 4, the inhibitory effect of Rtz on
pMMP1-Luc activity was completely abolished by co-expres-
sion of DN-PPAR-, supporting the implication of PPAR- in
this effect.
FIG. 2. Low concentrations of Rtz selectively inhibit IL-1-
induced proteoglycan degradation, gelatinolytic activities, and
MMP1 production. Rabbit articular chondrocytes were cultured at
high density and incubated for 18 h in 2% FCS/DMEM with or without
10 ng/ml IL-1 alone or combined with increasing concentrations of Rtz
from 0.5 to 10 M. A, production of total 35S-radiolabeled proteoglycans.
Chondrocytes were cultured as described above. Total PG production
was assayed after 18 h of incubation of the cells in sulfate-free medium
containing either IL-1 alone or combined with increasing concentra-
tions of Rtz. Each point was done in triplicate, and total PG was
expressed as percent of nontreated cells. Data are mean  S.D. of five
experiments performed with cells from different animal donors. **, p 
0.01 as compared with cells treated with IL-1 alone. B, gelatinolytic
activities. Culture medium was collected and subjected to gelatin zy-
mography as described under “Experimental Procedures.” The levels of
gelatinolytic bands were determined by scanning video densitometry.
The 72-kDa band is not modified by IL-1 or Rtz and was used as
internal control. C, Western blot confirmed the expression of MMP1 as
a single band identified at55 kDa. This figure is representative of one
of three separate experiments performed with different animals. Scan-
ning densitometry of the MMP1 band observed in culture medium from
chondrocytes treated with IL-1 alone or combined with 0.1, 0.5, or 1 M
Rtz was compared with that observed in nontreated cells. Equal loading
of protein was confirmed by Ponceau Red staining. Molecular mass
marker sizes are indicated on the right.
FIG. 3. Low concentrations of Rtz counteract IL-1-induced
mRNA expression of MMP1, -3, and -13 by a direct mechanism.
Cells were incubated as described in Fig. 2, in the absence or presence
of 1 M cycloheximide (Cyclohex). A, Northern blot. Total RNA (10 g)
was subjected to Northern blotting and hybridized with rabbit MMPs
probes. B, quantification of MMP1, -3, and -13 transcripts was per-
formed by densitometric analysis of autoradiographs and normalized to
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) signal. Data
are means  S.D. of five separate experiments performed with chon-
drocytes from different animals (**, p  0.01 versus IL-1-treated cells).
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The Inhibitory Effect of Rtz on MMP1 Promoter Transcrip-
tion Involves a Functional PPRE Situated at 83 to 71—We
have identified a degenerated PPRE sequence (AAAGCAT-
GAGTCA) in the 3.45-bp region of the rabbit MMP1 promoter,
located at83 to71 (GenBankTM accession number M17820).
EMSA analysis showed the formation of a thin retarded com-
plex between the PPRE and nuclear extract from nontreated
chondrocytes (Fig. 5A, lane 1). Addition of Rtz strongly en-
hances this complex (Fig. 5A, lane 2). The specificity of binding
activity was confirmed by competition experiments in the pres-
ence of an excess of either nonradioactive wild type PPRE or
consensus PPRE oligonucleotide (ACOA sequence) (Fig. 5A,
lanes 3 and 4). The signal was reduced and supershifted in the
presence of an anti-PPAR- antibody supporting the presence
of PPAR- in the complex (Fig. 5A, lane 5). Mutation into the
PPRE sequence resulted in oligonucleotides displaying no
PPAR- binding activity and, consequently, no supershifted
signal (Fig. 5A, lanes 6–9). Finally, the pMMP1-luciferase
construct, bearing the mutated PPRE, was transiently trans-
fected in chondrocytes. This experiment was done twice. Data
shown on Fig. 5B showed that this mutation leads to the loss
of Rtz inhibitory effect on IL-1-mediated MMP1 transacti-
vation. Together, these data demonstrate the following: (i)
Rtz-activated PPAR- binds the PPRE sequence situated at
83 to 71 in the MMP1 promoter, and (ii) PPAR- binding
is fundamental in the inhibition of IL-1-induced MMP1
transcription by Rtz.
The PPRE Sequence Situated at 83 to 71 in the MMP1
Promoter Is a Composite PPRE/AP1 Element and Promotes a
Mutually Exclusive PPAR- or AP1 Binding—This 83/71
PPRE sequence in the MMP1 promoter overlaps the proximal
AP1 site at 77 (TGAGTCA), which is considered a key
element in IL-1-induced MMP1 expression. EMSA analysis
using the composite PPRE/AP1 sequence was performed to
highlight the respective involvement of AP1 and PPAR-
binding activity. As shown in Fig. 6A, nuclear extracts from
chondrocytes treated with IL-1 alone elicited a DNA binding
complex (lane 2) that was partly supershifted with either the
anti-Fos family members (lane 3) or the specific anti-c-Jun
antibody (lane 4). In order to characterize the nature of the
Fos family member involved, we used specific antibodies
against c-Fos, Fra-1, and Fra-2. The association of c-Fos and
c-Jun antibodies totally supershifted the signal (Fig. 6A, lane
5). The isolated specific anti-c-Fos antibody substantially
supershifted the signal (Fig. 6A, lane 6), whereas anti-Fra-1
or anti-Fra-2 were ineffective (lanes 7 and 8). In addition, the
AP1 DNA binding complex was not supershifted upon addi-
tion of PPAR- antibody (Fig. 6A, lane 9). These data show
that IL-1-induced AP1 complex contains c-Fos/c-Jun pro-
teins but no PPAR--binding protein.
Another set of experiments was performed to study the fate
of the AP1 complex when Rtz was added together with IL-1.
As seen on Fig. 6B, the AP1 complex observed with IL-1 alone
(lane 1) was efficiently competed with a 50- and 100-fold molar
excess of unlabeled 83/71 PPRE sequence (lanes 2 and 3).
By comparison, this complex was not elicited by nuclear ex-
tracts from chondrocytes co-treated with IL-1 and Rtz,
whereas a new retarded species was observed (Fig. 6B, lane 4).
This new band was competed with unlabeled 83/71 PPRE
sequence (Fig. 6B, lane 5) and was supershifted after addition
of PPAR- antibody (lane 6). No supershift of this complex was
observed with PPAR- (Fig. 6C, lane 3) nor PPAR- (lane 4)
antibodies, indicating that PPAR- was present in this new
complex without other PPAR isotypes. Finally, neither c-Fos
FIG. 4. The inhibitory effect of Rtz on IL-1-induced MMP1
gene involves PPAR- at the transcriptional level. Chondrocytes
were transiently transfected with either the 3.45-kb pMMP1-luciferase
(Luc) construct alone or combined with wild type (WT) PPAR- or
mutated dominant negative (DN) PPAR- constructs and by -galacto-
sidase vector. Cells were treated with or without 1 M Rtz, 10 ng/ml
IL-1, or IL-1 combined with 0.5 or 1 M of Rtz for 18 h. Cell extracts
were assayed for luciferase activity as in Fig. 1. The activities were
corrected for transfection efficiency by -galactosidase activity and ex-
pressed as fold induction relative to the level in untreated cells. Each
point was done in triplicate, and this experiment was performed three
times with different animals for the dose-response curve and twice for
the dominant negative experiments. NS, not significant. Data are the
means  S.D.; ***, p  0.001 versus IL-1-treated cells.
FIG. 5. The functional PPRE sequence situated at 83 to 71
on the MMP1 promoter is required for PPAR binding and Rtz
inhibitory effect. A, EMSA. Nuclear extracts from nontreated (NT)
chondrocytes (lane 1) or with 1 M Rtz (lanes 2–9) were prepared as
described under “Experimental Procedures” and incubated with
[-32P]ATP-labeled oligonucleotides containing the wild type (WT) 83
to 71 PPRE (lanes 1–5) or a mutated version of the PPRE sequence
(lanes 6–9). Competition experiments were performed with a 100-fold
molar excess of nonradioactive WT PPRE (lane 3), canonical PPRE
sequence (lane 4), or a mutated PPRE (lanes 7 and 8). Identification of
the complexes was done with an anti-PPAR antibody (lanes 5 and 9).
*Ss indicated the PPAR- supershifted complex. B, transient expres-
sion. The 3.45-kb pMMP1-luciferase construct with the truncated 83
to 71 PPRE sequence was transiently transfected in chondrocytes as
described in Fig. 4. Each point was performed in triplicate. Cells re-
ceived 10 ng/ml IL-1 alone or combined with Rtz at concentrations
ranging between 0.1 and 10 M. Luciferase assay was performed as in
Fig. 4. Data are the means  S.D. of two separate experiments per-
formed with cells from different animals. NS, not significantly different
from IL-1-treated cells.
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nor c-Jun antibodies (Fig. 6C, lanes 6 and 7) modified this
signal, confirming the absence of AP1 proteins in this complex.
Taken together, these data demonstrate a mutually exclusive
binding of PPAR- and AP1 to the composite element 83 to
71 of MMP1 promoter.
We then investigated whether the PPAR inhibitory effect
on IL-1-induced MMP1 transcription might involve NF-B
transcription factors. EMSA analysis (Fig. 7) using an oligonu-
cleotide bearing the 3029 NFB-RE motif from the MMP1
promoter showed that no complex was observed using nuclear
extracts from nontreated or Rtz-treated cells (lanes 1 and 2).
IL-1 treatment of chondrocytes elicited the formation of two
DNA binding complexes (Fig. 7, lane 3), which were mostly
supershifted with anti-P50 antibodies (lane 4). The lower mo-
bility band was partly supershifted with anti-P65, whereas the
higher mobility band was not modified (Fig. 7, lane 5). These
data indicate that the lower mobility band mainly consists of
the p65-p50 heterodimer, whereas a p50 homodimer is present
in the higher mobility band. Rtz treatment had no significant
effect on any complex (lanes 6–8). In conclusion, no detectable
cross-talk occurs between IL-1-induced NF-B binding activ-
ity and Rtz-activated PPAR- at the 3029 NFB-RE.
DISCUSSION
We report here on the anti-cytokine effects of PPAR- acti-
vation in rabbit cartilage cells. Low concentrations (1 M) of
the classical pharmacological ligand Rtz selectively inhibit IL-
1-induced proteoglycan degradation and MMP1 expression.
The latter Rtz inhibitory effect targets the rabbit MMP1 pro-
moter via a novel composite element. PPAR- is constitutively
expressed in cultured rabbit articular chondrocytes as shown
by immunocytochemistry in Fig. 1A. EMSA experiments and
chondrocyte transient transfections with a 3X-PPRE-Lucifer-
ase construct demonstrated that endogenous PPAR- is func-
tionally activated by low doses of Rtz (0.1–1 M) with a maxi-
mum activity at 1 M (Fig. 1B). This is at variance with the
results of Fahmi et al. (3) who found a maximum stimulating
effect of such a reporter construct in cultured human chondro-
cytes by using a 100-fold higher concentration of Rtz. This
discrepancy may relate to a lower PPAR- content in cultured
human chondrocytes compared with rabbit cells.
We studied the effects of Rtz on a series of IL-1-induced
genes. Low concentrations of Rtz (0.1 to 1 M) negatively reg-
ulated specific subsets of IL-1-induced effects in chondrocytes,
whereas Rtz alone displayed no effect. A significant decrease of
proteoglycan degradation was associated with down-regulation
of 53/58-kDa gelatinolytic activity, MMP1 mRNA expression,
and MMP1 protein production (Fig. 2). Most interesting, low
concentrations of Rtz did not affect IL-1-induced COX2 mRNA
expression nor nitrite production, whereas both inflammatory
markers, as well as MMP1 expression, were reduced with high
doses (10 M) of Rtz (data not shown). This pharmacological
variance supports the notion that Rtz differently modulates
IL-1-induced inflammation and degradation in cartilage cells.
Inhibition of MMPs by low concentrations of natural as well as
synthetic PPAR- ligands has also been reported in other mod-
els (14, 29–32). The PPAR- mediation of MMPs inhibition has
been described but not fully demonstrated. We have investi-
gated the mechanism of the inhibitory effect of Rtz with a focus
on IL-1-induced MMP1 in chondrocytes.
The repression of IL-1-induced MMP1 overexpression by
Rtz is dose-dependent, direct, and occurs at the transcriptional
level, as observed by transient expression experiments using
the pMMP1-Luc vector (Fig. 4). In addition, the Rtz inhibitory
effect was enhanced in chondrocytes transiently transfected
with the wild type PPAR-, whereas it was abolished in cells
transfected with a dominant negative mutant PPAR-. This
further supports the implication of PPAR- in the inhibitory
effect of Rtz. PPAR- has been shown to modulate IL-1-in-
duced genes by several mechanisms including protein-protein
(NF-B, AP1, STAT) or DNA-protein interactions. Chung et al.
(33) have shown that PPAR- inhibits NF-B-driven tran-
scription by physically interacting with p50 and p65 proteins
as reported previously by Delerive et al. (34) for PPAR-. An
NF-B-responsive element has been characterized at position
3029 to 2994 in the MMP1 promoter, which is required for
maximal IL-1 transcriptional induction in synovial fibro-
blasts (23). In the present study, the 3029 to 2994
NFB-RE is shown to form DNA complexes involving p50/p50
homodimer and p50/p65 heterodimer proteins. The binding
activity of these complexes was not modified in the presence
of Rtz (Fig. 7), suggesting that Rtz-activated PPAR- does not
interfere with IL-1-induced NF-B binding activity in our
model.
FIG. 6. PPAR and AP1 binding to the PPRE sequence 83 to
71 of the MMP1 promoter is mutually exclusive. EMSA. Nuclear
extracts from chondrocytes either treated with IL-1 alone (A, lanes
2–9, and B, lanes 1–3) or with IL-1 plus Rtz (B, lanes 4–6, and C, lanes
2–7) were prepared and incubated with a [-32P]ATP-labeled oligonu-
cleotide containing the 83 to 71 composite PPRE/AP-1 element of
the rabbit MMP1 promoter. Specificity of binding was confirmed using
50- (B lane 2) or 100-fold (B, lanes 3 and 5) molar excess of unlabeled
corresponding oligonucleotide. Identification of each complex was done
with the following antibodies: anti-Fos family members (A, lane 3),
anti-c-Jun (A, lane 4, and C, lane 7), anti-c-Fos plus anti-c-Jun (A, lane
5), anti-c-Fos (A, lane 6, and C, lane 6), anti-Fra-1 (A, lane 7), anti-Fra-2
(A, lane 8), and anti-PPAR- (A, lane 9, and B, lane 6, and C, lane 5),
anti-PPAR- (C, lane 3), and anti-PPAR- (C, lane 4) antibodies. A and
C, lanes 1 are with radiolabeled 83 to 71 PPRE element alone. *Ss
indicated the supershifted signal of each corresponding DNA complex.
FIG. 7. No detectable cross-talk occurs between IL-1-induced
NF-B binding activity and Rtz-activated PPAR- at the 3029
NFB-RE of MMP1 promoter. EMSA. Nuclear extracts from chon-
drocytes incubated in basal conditions (lane 1), treated with Rtz alone
(lane 2), with IL-1 alone (lanes 3–5), or with IL-1 	 Rtz (lanes 6–8)
were prepared and incubated with [-32P]ATP-labeled oligonucleotide
containing the 3029 NFB-RE. Identification of the NF-B complexes
was done with anti-p50 (lanes 4 and 7) and anti-p65 (lanes 5 and 8)
antibodies. *Ss indicated the supershifted signal of each corresponding
DNA complex. NS indicated a nonspecific complex.
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Activated PPAR- also acts through DNA binding interac-
tion with its cognate PPRE sequences (direct repeats with
single spacing nucleotide, DR1) located in the promoter of
target genes. For example, the activated PPAR- inhibits reg-
ulated on activation normal T cell expressed and secreted
(RANTES) transcription and protein production in endometri-
otic stromal cells through a specific PPRE at 334 to 322
upstream from the RNA polymerase start site (35). We have
identified a degenerated DR1 sequence (AAAGCATGAGTCA)
located at 83 to 71 in the rabbit MMP1 promoter. Gel
mobility shift and supershift assays showed that this cis-acting
element binds PPAR-, whereas no binding activity was ob-
served with a mutated PPRE (Fig. 5A). In addition, Rtz failed
to inhibit MMP1 promoter activity when chondrocytes were
transfected with a pMMP1-Luc vector bearing this mutated
PPRE (Fig. 5B). Altogether these data demonstrate that the
inhibitory effect of Rtz on IL-1-induced MMP1 gene transcrip-
tion implicates PPAR- binding on the 83 to 71 cis-acting
sequence of the MMP1 promoter.
The next question was to study whether the reduced IL-1-
induced MMP1 expression by Rtz was because of an interaction
between PPAR- and AP1 binding activities on the 83 71
sequence of the MMP1 promoter. Fahmi et al. (36) have shown
previously that 15d-PGJ2, a lower affinity PPAR- ligand, re-
duces IL-1-induced MMP1 expression in human synovial fi-
broblasts and inhibits AP1 DNA binding activity. They con-
cluded that 15d-PGJ2 negatively regulated MMP1 expression
by interfering with AP1 activation, although neither the
PPAR- dependence of the 15d-PGJ2 inhibitory effect nor the
PPAR-/AP1 interactions were analyzed. Their EMSA experi-
ment describing the decreased AP1 binding activity was per-
formed with an oligonucleotide corresponding to the restricted
AP1 sequence 77–71 of the MMP1 promoter, which does not
comprise the full overlapping PPRE 83–71 sequence. In ad-
dition, BRL49653 (Rtz) was much less effective than 15d-PGJ2,
with an inhibitory effect only observed at very high concentra-
tions (10–100 M) far from its Kd value for PPAR-, and no
information was provided about the effect of Rtz on the AP1
binding activity. Altogether these data supported a PPAR--
independent pathway for the anti-MMP1 effect of the 15d-
PGJ2. Indeed, 15d-PGJ2 has been shown to reduce AP1 acti-
vation in several anti-inflammatory responses by interacting at
multiple levels along the AP1 pathway (37). More recently, Mix
et al. (38) showed that 15d-PGJ2 decreased IL-1-induced
MMP1 expression in the human SW-1353 chondrosarcoma cell
line, through a novel PPAR--independent mechanism that
requires Smad signaling.
In the present work, a series of EMSA analyses were per-
formed with the composite PPRE/AP1 element in order to high-
light the respective involvement of PPAR- and AP1 binding
activities, in cells co-treated with IL-1 and Rtz (Fig. 6). The
IL-1-induced AP1 DNA binding activity observed in chondro-
cytes was shown to contain immunoreactive c-Fos and c-Jun
proteins (Fig. 6A). This is at variance with the AP1 complex
induced in fibroblast growth factor-stimulated MMP1 in
MC3T3-E1 osteoblasts and in PMA-induced MMP1 in rabbit
fibroblasts (39, 40). In these cases, the AP1 complex was shown
to contain Fra-1- or Fra-2-binding proteins at the 77 site of
the MMP1 promoter. However, our data are in accordance with
those from Chamberlain et al. (41) and Hamid et al. (42) who
showed an up-regulation of MMP1 by PMA or IL-1 involving
a c-Fos-c-Jun AP1 complex at 77 to 69 of the promoter.
Finally, the IL-1-induced complex bound to the AP1 element,
characterized under the present experimental conditions, was
not recognized by anti-PPAR- antibodies indicating the ab-
sence of PPAR- proteins in this complex.
When nuclear extracts were prepared from IL-1 and Rtz
co-treated cells, the AP1 complex totally disappeared, whereas
a differently shifted complex was observed (Fig. 6B). This new
complex is further supershifted in the presence of an anti-
PPAR- antibody but not with c-Fos and c-Jun antibodies and
not with PPAR- or PPAR- antibodies, indicating that this
complex only contain PPAR- (Fig. 6C). Taken together, our
data demonstrate that AP1 and PPAR bindings on the com-
posite PPRE/AP1 sequence are mutually exclusive.
Our data are consistent with a new PPAR--dependent in-
hibitory mechanism of Rtz on IL-1-induced MMP1 expression
in chondrocytes. This inhibition appears to be mediated
through binding competition between PPAR and the AP1
complex for the composite PPRE/AP1 at position 83 to 71.
As direct repeat (DR1) cis-acting elements can be recognized by
a variety of transcription factors including the chicken ovalbu-
min upstream promoter-transcription factor or RAR-related
orphan receptor (43), we cannot exclude the possibility that in
our model other transcription factors may also bind this com-
posite element and take part into the transcriptional down-
regulation of the MMP1 gene.
Whether PPAR--dependent inhibition is restricted to
MMP1 or occurs with other MMPs remains to be investigated.
In the present work Rtz was shown to inhibit IL-1-induced
MMP9 gelatinolytic activities and MMP3 and MMP13 mRNA
levels. PPAR agonists were also found to inhibit MMP3 ex-
pression in human rheumatoid fibroblast-like synoviocytes
(44). Down-regulation of MMP9 by natural (15d-PGJ2) and
synthetic (GW7845) PPAR- ligands in PMA-stimulated THP-1
monocytes has been consistently observed (31). An inhibition of
MMP13 expression by Rtz was also reported by Fahmi et al. (3)
in human chondrocytes. Similarly to the MMP1 gene situation,
AP1 has been shown to be involved in the up-regulation of
MMP3 in meshwork cells (45), MMP9 in human vascular
smooth muscle cells (46), and MMP13 in osteoblasts (27). We
searched for the presence of a DR1-PPRE overlapping an AP1
element in the promoter of MMP3, MMP9, and MMP13. An
AP-1 site at position 1929 and a PPRE at position 1950
have been recently identified in the murine MMP3 (47). Com-
puter analysis of the human MMP3 (GenBankTM accession
number AF405705) allowed us to identify a degenerated DR1-
PPRE overlapping an AP1 element at position 73 to 63
(CAAGGATGAGTCA). Two PPREs were recently identified in
the rat MMP9 promoter (48). Most interesting, we found a
degenerated PPRE sequence overlapping an AP1 element
(TGAGTCAGAAGTTCG) at position 1661 to 1646 in the
human MMP9 promoter (GenBankTM accession number AF538
844). Finally, we found a DR1-PPRE/AP1 sequence (AAGT-
GATGACTCA) at position 80 to 67 in the human (Gen-
BankTM accession number X81640), rat (GenBankTM accession
number AY135636), and dog (GenBankTM accession number
AF384859) promoters of MMP13. We thus speculated that the
Rtz inhibitory effect on IL-1-induced MMP3, -9, and -13 may
occur through a mechanism similar to the Rtz effect on MMP1.
In conclusion, we have determined that Rtz-activated
PPAR- represses MMP1 transcription in chondrocytes, by
interfering with the binding of c-Fos/c-Jun proteins to the
promoter sequences situated at 83–71. Further studies will
be performed to confirm that this interaction occurs in vivo in
the chromatin environment and to determine whether other
co-factors participate in this effect. Nevertheless, PPAR-
appears able to counteract the IL-1-induced proteoglycan
degradation and MMP1 transcription acting as a protective
mechanism in cartilage. This beneficial function can be elic-
ited by low concentrations of Rtz (and probably other thiazo-
lidinediones), in contrast with the much less manageable
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amounts required with most other PPAR- ligands. Thiazo-
lidinediones thus deserve consideration for clinical testing in
degenerative cartilage diseases.
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